The Mast Cell Disease Society, Inc.

Name

The Mast Cell Disease Society, Inc.

Legal name

The Mast Cell Disease Society, Inc.

Website

https://tmsforacure.org

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Sterling, Massachusetts

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Individual Donations: Individual donors contribute via the website donation portal. TMS offers options for standard gifts, memorial donations, tribute donations, and birthday fundraising campaigns. Donations are tax-deductible as TMS is a 501(c)(3) organization (EIN# 52-1959601).
2. Corporate Sponsorship (Partner in Hope Program): Pharmaceutical companies sponsor TMS through tiered partnership levels (Titanium, Platinum, Silver, Bronze). Sponsors include Blueprint Medicines (exclusive Titanium Partner) and Cogent Biosciences (Platinum Partner), as well as event sponsors for virtual symposia.
3. Planned Giving / Legacy Gifts: TMS accepts bequests through wills and living trusts, beneficiary designations, charitable gift annuities, charitable remainder trusts, IRA charitable rollovers, and real estate gifts. These legacy gifts provide long-term financial sustainability.
4. Fundraising Campaigns and Events: TMS organizes fundraising campaigns including named funds (Wyatt Warrior Fund, Sarah Gittleman Fund, Adam Thrasher HCP Education Fund, Julie Smith Yolles MCAS Wellness Research Fund), community fundraisers, and event-based fundraising. Corporate matching gift programs amplify individual donations.
5. Gift Card Fundraising (RaiseRight): TMS operates a RaiseRight gift card fundraising team where community members purchase gift cards through the platform, and a percentage of each sale is contributed back to TMS, providing a frictionless ongoing revenue stream.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

Core offering

TMS is a 501(c)(3) nonprofit patient advocacy organization that provides free educational resources, community support, and research infrastructure for individuals affected by mast cell diseases and the healthcare providers who treat them. Core deliverables include disease-specific patient guides, an emergency room protocol system, the CME-accredited TeleECHO program for physicians, an upcoming MCD Patient and Provider Registry, clinical trial navigation resources, and community programs (support groups, awareness days, fundraising campaigns). All offerings are free to patients, caregivers, and providers, funded entirely through donations, corporate sponsorships, and fundraising.

Product overview

The Mast Cell Disease Society (TMS) is a nonprofit patient advocacy organization that offers a unified suite of educational resources, support programs, and community tools for individuals affected by mast cell diseases. Rather than a traditional product-platform architecture, TMS provides interconnected services including patient resource guides, disease-specific brochures, an Emergency Room Protocol system, the TeleECHO Program for healthcare provider education with CME credits, clinical trial resources, the upcoming MCD Patient and Provider Registry, a webinar library, a book club, printable infographics, and a comprehensive fundraising platform. These offerings work together to fulfill TMS's mission of providing trusted resources, community, and research to help patients understand, manage, and live fully with mast cell diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Mast Cell Disease TeleECHO Program A free virtual, case-based learning series for healthcare providers focused on evaluating, diagnosing, and treating patients with mast cell disease. Offered in partnership with Project ECHO and accredited by ACCME, ACPE, and ANCC, the program provides CME credits to participating physicians.
• MCD Patient and Provider Registry An upcoming patient and provider registry for mast cell diseases designed to collect real-world data from patients and providers to advance research and clinical understanding of mast cell diseases.
• Emergency Room Protocol Program

Quantifiable outcome

• Over $20,000 raised in a single community fundraiser (black belt testing campaign)
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Mastocytosis and Mast Cell Diseases International CommitteecoreStrategic or Co-development Partner · 1 January 2018The International Committee was formed in 2018 by 23 organizations from 21 countries, with TMS as a founding member. The committee organizes the annual October 20 International Mastocytosis & Mast Cell Diseases Awareness Day and produces patient fact sheets and survey results. Partners include RARE Revolution Magazine as content partner.
• Blueprint Medicines (a Sanofi company)coreStrategic or Co-development PartnerBlueprint Medicines is the exclusive Titanium Partner of TMS for 2026, having made a multi-year commitment to support TMS's mission. Blueprint also sponsors the Colors of SM patient storytelling program (in partnership with Twist Out Cancer), Rare Disease Day fact sheets, and awareness day resources. The company develops targeted therapies for mast cell diseases including avapritinib.
• Cogent BiosciencescoreStrategic or Co-development PartnerCogent Biosciences is a Platinum Partner for both 2025 and 2026, having renewed its commitment to TMS's work. Cogent also sponsors TMS's virtual symposium (Gold Event Sponsor for TMS Together 2025) and Rare Disease Day awareness resources as a Gold Sponsor. The company is developing targeted therapies for systemic mastocytosis.
• Project ECHOcoreStrategic or Co-development PartnerProject ECHO (Extension for Community Healthcare Outcomes) partners with TMS to deliver the Mast Cell Disease TeleECHO program — a virtual, case-based learning series for healthcare providers. Project ECHO is jointly accredited by ACCME, ACPE, and ANCC to provide CME credits. This partnership enables TMS to offer accredited medical education to physicians at no cost.
• National Organization for Rare Disorders (NORD)minorStrategic or Co-development PartnerTMS holds a 2024 Platinum membership in NORD, participating in annual Rare Disease Day at NIH events and benefiting from NORD's network and advocacy resources for rare disease organizations.
• NovartisminorGTM or Marketing PartnerNovartis organized a Chronic Hives Summit as part of the AAAAI 2026 conference, where TMS participated in a collaborative session with other patient advocacy organizations including Allergy & Asthma Network, Asthma and Allergy Foundation of America, Global Allergy & Airways Patient Platform, and We CU to review organizational work and discuss collaboration.
• Twist Out CancerminorStrategic or Co-development PartnerTwist Out Cancer is a nonprofit providing creative arts programs to people living with health conditions. Partnered with Blueprint Medicines and TMS on the Colors of SM: Expressions of Life with Systemic Mastocytosis program, which pairs SM patients with artists to create works reflecting their journey.
• Walter Reed National Military Medical CentercoreStrategic or Co-development PartnerWalter Reed is designated as a Mast Cell Disease Center of Excellence. Dr. Nathan Boggs and his team conduct mast cell disease clinical trials and non-interventional research studies, store samples in their USU lab, and collaborate with TMS on improving screening and diagnostic algorithms.
• Moffitt Cancer CenterminorStrategic or Co-development PartnerMoffitt Cancer Center is referenced as the site where a TMS patient was diagnosed with ISM and received access to avapritinib through compassionate use. Moffitt has expertise in treating mastocytosis patients.
• RARE Revolution MagazineminorGTM or Marketing PartnerRARE Revolution Magazine is a content partner for the 2025 Awareness Day campaign, collaborating with TMS, Blueprint Medicines, and Cogent Biosciences to produce fact sheets and patient resources.
• Allergy & Asthma NetworkminorGTM or Marketing PartnerPartnered with TMS at the Novartis-organized Chronic Hives Summit during AAAAI 2026. Both organizations discussed collaboration to fill existing gaps in patient support for chronic hives and broader mast cell disorders.
• Asthma and Allergy Foundation of AmericaminorGTM or Marketing PartnerPartnered with TMS at the Novartis-organized Chronic Hives Summit during AAAAI 2026, reviewing collaborative work on chronic hives support and discussing strategies to better serve patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Asthma and Allergy Foundation of America (AAFA): A leading US patient advocacy nonprofit serving patients with asthma, allergies, and related immunological conditions. Comparable as a fellow participant in the Novartis Chronic Hives Summit with TMS, sharing similar revenue models (corporate sponsorship from pharma, individual donations), patient education resources, and provider outreach through medical society partnerships (AAAAI).
• Allergy & Asthma Network: A nonprofit patient advocacy organization focused on allergy, asthma, and related immunological conditions including mast cell disorders. Directly comparable as an active collaborator with TMS (joint participation in the Novartis Chronic Hives Summit at AAAAI 2026) sharing the same patient/provider dual-channel model, pharmaceutical sponsorship structure, and CME-accredited provider education programs.
• Histiocytosis Association: A US patient advocacy nonprofit for histiocytic disorders (including Langerhans cell histiocytosis), which involve mast cell biology overlap. Comparable as a fellow rare disease 501(c)(3) with a comparable operating model (small staff, pharmaceutical partnerships, medical advisory board, patient/provider education, research grants, and NORD membership).
• American Partnership for Eosinophilic Disorders (APFED): A US nonprofit patient advocacy organization for eosinophil-associated diseases, which have clinical and immunological overlap with mast cell diseases. Comparable as a fellow rare disease advocacy nonprofit with similar dual patient/HCP audience model, pharmaceutical sponsorship tiers, awareness day programming, and CME-accredited provider education.
• The Mast Cell Society (formerly TMS UK / Mast Cell Action): A UK-based patient advocacy charity for mast cell diseases. The closest direct international peer to TMS, sharing the same disease focus (mastocytosis, MCAS, HαT), similar patient resource model, and overlapping pharmaceutical partnerships (Blueprint Medicines supports both organizations).
• Children's Tumor Foundation: A US patient advocacy nonprofit dedicated to neurofibromatosis, another rare disease. Comparable in scale and structure (similar headcount, similar donation-based revenue model, similar pharmaceutical partnerships, patient registry programs) and shares the rare disease advocacy playbook of awareness days, research grants, and clinical trial navigation.

Broad incumbents

• National Eczema Association: A US patient advocacy nonprofit for eczema/atopic dermatitis, another condition often co-managed with mast cell disorders. Comparable as a fellow 501(c)(3) patient advocacy nonprofit with tiered pharmaceutical sponsorship, patient registry (NEA's Eczema Patient Insights Network), CME programs, and similar digital education and community-building infrastructure.
• Lupus Foundation of America: A well-established US rare autoimmune disease patient advocacy nonprofit. Comparable as a fellow 501(c)(3) with a multi-decade operating history, pharmaceutical partnership model (tiered sponsorship from companies developing lupus therapies), CME-accredited provider education, patient registry infrastructure, and dual patient/HCP audience strategy.
• National Organization for Rare Disorders (NORD): The leading US umbrella advocacy organization for rare diseases, of which TMS is a Platinum member. NORD is comparable as a fellow patient advocacy nonprofit operating at a broader (700+ disease) scale with similar revenue streams (corporate sponsorship, individual giving, planned giving) and overlapping programs (Rare Disease Day, registry initiatives, CME provider education).

Emerging players

• Chronic Urticaria & Angioedema Society (CURAS): An emerging patient advocacy organization focused on chronic urticaria and angioedema — conditions with significant mast cell biology overlap. Comparable as a smaller, more recently established nonprofit in the adjacent immunological space, sharing the same pharmaceutical sponsor ecosystem (Blueprint, Novartis, Cogent) and similar awareness day and CME programming models.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/MCDiseasesUnite
• Facebookfacebook.com/TMSforacure
• LinkedInlinkedin.com/company/tmsforacure
• Instagraminstagram.com/mcdiseasesunite

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Mast Cell Disease Society, Inc.